Testing a new imaging agent for brain and pancreatic tumors
Part of Brain & nervous system, Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase study tests a new imaging agent that may help see certain solid tumors (like brain cancer or pancreatic cancer) more clearly. You will receive a single injection of a radioactive tracer, then have several scans over a few days to see where the tracer goes and how long it stays.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with either glioblastoma (a type of brain tumor) or pancreatic cancer, and your tumor is at least 1 cm (pea-sized) on an MRI or CT scan
- You are generally able to take care of most daily tasks (Karnofsky score of 60 or higher)
- Your blood counts and kidney/liver function are within certain limits (your doctor can check)
- You are not pregnant, breastfeeding, and agree to use birth control if needed
- You are not currently taking statin cholesterol medications (or can stop them for a few days before the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special imaging scan (PSMA PET) before and after the drug bevacizumab can help see how the drug affects glioblastoma tumors. It aims to understand tumor changes better, which may help guide future treatments.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This Phase 2 study tests a special PET scan tracer to help doctors spot tissue damage after radiation treatment in people with certain lung or pancreatic cancers. The goal is to improve detection and planning around chemoradiation and surgery.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
This study tests a new imaging agent that may help see pancreatic and head and neck cancers more clearly on a PET/CT scan. It is for people newly diagnosed who have not yet started treatment, to see if the agent is safe and works well.
This trial tests an experimental drug that targets tumors with a special protein detected by a PET scan. It may help treat certain cancers like breast, head and neck, pancreatic, or brain cancers that have grown despite prior treatment.
Hear when a new Glioblastoma Multiforme (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.